170 related articles for article (PubMed ID: 26646859)
1. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
2. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
3. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
4. Access in all areas? a round up of developments in market access and health technology assessment: part 4.
Beattie A; Treharne C; Ramagopalan SV
J Comp Eff Res; 2024 Jun; 13(6):e240060. PubMed ID: 38647164
[TBL] [Abstract][Full Text] [Related]
5. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
6. Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality.
Capuozzo M; Celotto V; Zovi A; Langella R; Ferrara F
Eur J Health Econ; 2024 Feb; 25(1):1-5. PubMed ID: 37878195
[TBL] [Abstract][Full Text] [Related]
7. Do France, Germany, and Italy agree on the added therapeutic value of medicines?
Casilli G; Lidonnici D; Jommi C; De Nigris M; Genazzani AA
Int J Technol Assess Health Care; 2023 Aug; 39(1):e54. PubMed ID: 37580971
[TBL] [Abstract][Full Text] [Related]
8. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
Robinson MF; Mihalopoulos C; Merlin T; Roughead E
Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
[TBL] [Abstract][Full Text] [Related]
9. [Medicines use in Italy. 2020 OsMed National Report.].
Zito S; Fortinguerra F; Pierantozzi A; Ambrosino F; Traversa G; Trotta F; Da Cas R; Cangini A
Recenti Prog Med; 2021 Oct; 112(10):659-667. PubMed ID: 34647536
[TBL] [Abstract][Full Text] [Related]
10. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers.
Russo P; Mennini FS; Siviero PD; Rasi G
Ann Oncol; 2010 Oct; 21(10):2081-2087. PubMed ID: 20335370
[TBL] [Abstract][Full Text] [Related]
11. The Italian experience with the use of monitoring registers attached to negotiated agreements (MEAs) of the Italian Medicines Agency is a tool for governance and clinical appropriateness.
Capuozzo M; Celotto V; Ottaiano A; Zovi A; Langella R; Ferrara F
J Cancer Policy; 2023 Dec; 38():100450. PubMed ID: 37922982
[TBL] [Abstract][Full Text] [Related]
12. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Ferrario A; Kanavos P
Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
[TBL] [Abstract][Full Text] [Related]
13. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
14. [ProMoFIA_Oncologic: monitoring project of the innovative oncology drugs in Abruzzo].
Belfiglio M; Sichetti D; Romero M; Orsini A;
Recenti Prog Med; 2013 Jun; 104(6):241-5. PubMed ID: 23801227
[TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance in Italy: An overview.
Mazzitello C; Esposito S; De Francesco AE; Capuano A; Russo E; De Sarro G
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S20-8. PubMed ID: 24347976
[TBL] [Abstract][Full Text] [Related]
16. Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.
Iacovino ML; Celant S; Tomassini L; Arenare L; Caglio A; Canciello A; Salerno F; Olimpieri PP; Di Segni S; Sferrazza A; Piccirillo MC; Beretta GD; Pinto C; Blasi L; Cinieri S; Cavanna L; Di Maio M; Russo P; Perrone F
Lancet Reg Health Eur; 2024 Jun; 41():100912. PubMed ID: 38665620
[TBL] [Abstract][Full Text] [Related]
17. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA).
Onder G; Bonassi S; Abbatecola AM; Folino-Gallo P; Lapi F; Marchionni N; Pani L; Pecorelli S; Sancarlo D; Scuteri A; Trifirò G; Vitale C; Zuccaro SM; Bernabei R; Fini M;
J Gerontol A Biol Sci Med Sci; 2014 Apr; 69(4):430-7. PubMed ID: 23913935
[TBL] [Abstract][Full Text] [Related]
19. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system.
Galeone C; Bruzzi P; Jommi C
BMJ Open; 2021 Jan; 11(1):e041259. PubMed ID: 33441356
[TBL] [Abstract][Full Text] [Related]
20. [Drug evaluation: new requirements and perspectives].
Addis A; Rocchi F
Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
